Suppr超能文献

理解套细胞淋巴瘤患者的健康相关生活质量。

Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma.

机构信息

Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisconsin, 1111 Highland Avenue, Room 4031, Madison, WI 53705, USA.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.

出版信息

Hematol Oncol Clin North Am. 2020 Oct;34(5):971-982. doi: 10.1016/j.hoc.2020.06.011. Epub 2020 Aug 5.

Abstract

Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients' health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients' lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.

摘要

套细胞淋巴瘤(MCL)是一种独特的淋巴瘤,其临床病程具有异质性,且缺乏共识性的治疗方法。MCL 通常在确诊时采用免疫化疗,在复发时采用慢性治疗。尽管治疗取得了显著进展,但 MCL 仍无法治愈。维持患者的健康相关生活质量(HRQOL)是一个重要的治疗目标。HRQOL 评估阐明了疾病及其治疗对患者生活的影响。本综述强调了 HRQOL 评估在 MCL 中的相关性,评估了现有证据、当前 HRQOL 评估中的知识空白和挑战,并确定了改善 MCL 患者 HRQOL 评估的未来方向。

相似文献

1
Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma.
Hematol Oncol Clin North Am. 2020 Oct;34(5):971-982. doi: 10.1016/j.hoc.2020.06.011. Epub 2020 Aug 5.
2
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
J Hematol Oncol. 2020 Mar 17;13(1):21. doi: 10.1186/s13045-020-00855-9.
3
Current trials for frontline therapy of mantle cell lymphoma.
J Hematol Oncol. 2018 Jan 27;11(1):13. doi: 10.1186/s13045-018-0556-x.
4
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Oncotarget. 2016 Jul 26;7(30):48692-48731. doi: 10.18632/oncotarget.8961.
5
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
Leuk Lymphoma. 2011 Jan;52(1):24-33. doi: 10.3109/10428194.2010.532893. Epub 2010 Dec 6.
6
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
Int J Mol Sci. 2019 Sep 8;20(18):4417. doi: 10.3390/ijms20184417.
7
Should there be a standard therapy for mantle cell lymphoma?
Future Oncol. 2011 Feb;7(2):227-37. doi: 10.2217/fon.10.189.
8
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Curr Oncol Rep. 2022 Oct;24(10):1313-1326. doi: 10.1007/s11912-022-01297-x. Epub 2022 May 31.
9
Treatment options for mantle cell lymphoma.
Expert Opin Pharmacother. 2015;16(16):2497-507. doi: 10.1517/14656566.2015.1087507. Epub 2015 Sep 11.
10
Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Clin Cancer Res. 2015 Sep 1;21(17):3853-61. doi: 10.1158/1078-0432.CCR-15-0488. Epub 2015 Jun 9.

引用本文的文献

2
Tackling Mantle Cell Lymphoma in Europe.
Healthcare (Basel). 2022 Sep 3;10(9):1682. doi: 10.3390/healthcare10091682.

本文引用的文献

2
Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized Trials.
Hemasphere. 2018 Jul 27;2(4):e136. doi: 10.1097/HS9.0000000000000136. eCollection 2018 Aug.
3
Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Biol Blood Marrow Transplant. 2020 Jan;26(1):157-161. doi: 10.1016/j.bbmt.2019.09.007. Epub 2019 Sep 12.
5
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.
Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18.
7
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.
ESMO Open. 2017 Nov 23;2(5):e000284. doi: 10.1136/esmoopen-2017-000284. eCollection 2017.
9
Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.
Cancer. 2018 Mar 1;124(5):991-997. doi: 10.1002/cncr.31133. Epub 2017 Nov 13.
10
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验